Clinical Trial

Impact Of The Gut Microbiota On Host Cells Energy Metabolism in Health And In Inflammatory Bowel Disease

Study acronym: ENERGISED
Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
Inflammatory Bowel Disease (IBD) often leads to poor disease control and reduced quality of life. Changes in the gut microbiota may disrupt the energy metabolism of immune cells, contributing to IBD. This study will examine how gut microbiota affects immune cell metabolism in healthy adults and IBD patients. Healthy volunteers will be tested before and after a short antibiotic treatment, while IBD patients will be tested once. Energy metabolism will be measured using SCENITH, a method that analyzes metabolic activity in blood immune cells. Participants will also receive a special form of fiber (13C-labeled inulin) to track how gut bacteria break down and use this nutrient. Blood, urine, and stool samples will be analyzed to follow the metabolic fate of inulin. DNA and RNA from stool will be studied to identify which bacteria metabolize the labeled fiber.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2025-12-10.
Status change: Not Yet Recruiting → Recruiting 2026-03-11
Trial Details
NCT Number NCT07300553
Lead Sponsor Assistance Publique - Hôpitaux de Paris
Collaborators: INSERMUMR938, CRB SAT APHP.SU Saint-Antoine hospital
Conditions IBD, Crohn Disease, Ulcerative Colitis (UC)
Enrollment 45 participants
Start Date 2026-01-02
Primary Completion 2026-11 (estimated)
Study Completion 2027-08 (estimated)
Updated on ClinicalTrials.gov 2026-03-12